The decision of using immunotherapy wasn’t approved before because it concerns to ethical part of questions. The price for Keytruda (pembrolizumab drug) can be expensive, by the way, every year around 400-500 patients are using them as a treatment. The Norwegian Medicines Agency approved that this method of treatment can have positive effect. MSD drug company create a negotiable level of prices, thats why treatment can characterised as a cost-effective.
Hospital managers afraid that implementing the plan, to use immunotherapy as the first method of treatment in Norway, can have influence to the hospital budget and effect for other patients who will be treated in their hospitals with other group of health problems.
Read other news on our city site of Oslo.